Clinical Trial Update: CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for a CD30-targeted CAR T-cell therapy for relapsed/refractory CD30-positive peripheral T-cell lymphoma, currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• CD30 CAR T-cell therapy

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: RECRUITING